Research programs working toward an HIV cure. Covers reservoir reduction, prevention policy, tumor-like tissue models, and vaccine development.
Researchers found that starting combined antiretroviral therapy against simian immunodeficiency virus two weeks after infection significantly reduced chronic immune activation, SIV replication, and latent TB reactivation. This study contributes to the growing evidence on the complex interaction between HIV and tuberculosis.
A woman with HIV has achieved 14 months of undetectable HIV levels following a cord blood stem cell transplant to treat acute myeloid leukemia. The study suggests that CCR5Δ32/Δ32 cord stem cell transplantation may be an effective method for achieving HIV remission and cure in individuals requiring such transplants.
A meta-analysis of 33 interventions targeting STI/HIV risk reduction found that including pleasure can improve knowledge and attitudes around sex, as well as condom use. The review suggests revisiting sexual education approaches that acknowledge the pleasurable aspects of human experience.
Researchers at The Wistar Institute have developed a DNA-encoded immunogen that produces tier-2 neutralizing antibodies in mice, opening up new possibilities for HIV vaccine development. The study demonstrates the potential of using native-like trimer to generate broadly neutralizing antibody responses.
Researchers have identified a new highly virulent HIV variant in the Netherlands, known as VB variant, which shows significant differences in immune system recovery and survival compared to other variants. Early diagnosis and treatment are crucial to prevent damage from this more rapid decline in immune strength.
A new study by CUNY SPH researchers estimates that nearly 40% of children living with HIV in sub-Saharan Africa are undiagnosed, highlighting the urgent need for improved pediatric testing coverage. The study found that only 55% of children on ART had suppressed viral loads, underscoring the importance of early diagnosis and treatment.
A new study published in Annals of Internal Medicine suggests that the value of long-acting injectable cabotegravir for HIV prevention is comparable to generic oral alternatives. The study found that CAB-LA's superiority over oral PrEP among high-risk individuals would not justify a large price difference.
A Phase 1 clinical trial conducted by University of Minnesota researchers demonstrates the safety and efficacy of a novel immunotherapy drug in treating human immunodeficiency virus (HIV). Participants showed a significant decrease in HIV-infected cells in their blood for up to six months following treatment.
A recent survey by Johns Hopkins Medicine researchers found that about 22% of young sexual minority males and transgender females engage in transactional sex. The practice is associated with HIV exposure, substance use disorder, and unstable housing. Researchers plan to develop interventions to address economic and social vulnerabilities.
A meta-analysis of 87 surveys from 35 African countries found that nearly one in ten sexually active men have paid for sex and are 50% more likely to be living with HIV. Men who pay for sex should be recognized as a priority population for HIV prevention efforts.
Scientists at Scripps Research have devised a method that can rapidly characterize antibodies using high-resolution, low-temperature electron microscopy (cryo-EM). This technique enables the identification of specific antibodies in fraction of time needed for traditional approach.
Researchers at FAU are developing an affordable, disposable self-testing HIV-1 chip that can detect HIV from whole blood samples and measure viral load without refrigeration or skilled technicians. The technology aims to increase access to HIV testing and improve treatment outcomes in any setting.
A UCLA-led team has improved a method to kill HIV-infected cells, using natural killer cells to target and eliminate them. The approach could lead to reducing or eliminating the virus from infected individuals who rely on medication.
A global trial led by UCL found that a dolutegravir-based regimen reduced treatment failure among young people aged three to 18 by around 40% compared to standard treatments. The study also showed better growth and lipid profiles in children receiving dolutegravir, making it an effective option for treating HIV in children.
Research reveals that HIV-positive individuals with cocaine addiction struggle to withhold behavioral responses due to distinct brain activity patterns. This finding highlights the need for targeted interventions to address dual diagnosis in recovery programs.
Researchers have discovered that HIV drugs may be effective in treating low-grade brain tumours, specifically meningioma and acoustic neuroma. High levels of HERV-K proteins were found to stimulate the growth of these tumours, and targeted drugs have been identified to reduce their growth.
A new study by Kaiser Permanente researchers has found that people with HIV are at higher risk of developing heart failure than those without the condition. The study identified significant differences in heart failure risk among various demographics, including age, sex, and ethnicity.
A novel mRNA-based HIV vaccine has been shown to be safe and elicit desired immune responses in mice and non-human primates. The vaccine prompted a 79% lower per-exposure risk of infection by simian-human immunodeficiency virus compared to unvaccinated animals.
A Rutgers-led study found that racial biases among health care providers may limit the number of Black women taking a daily pill to prevent HIV infection. The study also highlights how providers' racist beliefs can disadvantage Black women's access to PrEP, a medication up to 92% effective when taken correctly.
A new study links the composition of gut microbiome before infection to HIV susceptibility and progression. Men who contracted HIV in the early days of the pandemic had a greater relative abundance of pro-inflammatory vs. anti-inflammatory gut microbes, which contributed to their increased risk of developing AIDS.
Researchers have designed a new nanoparticle adjuvant that significantly improves antibody production following vaccination against HIV, diphtheria, and influenza. The adjuvant speeds up lymph flow to lymph nodes, helps antigens reach B cells before breaking down, and activates inflammatory cytokines for a stronger response.
A recent study found that 19.9% of trans feminine individuals and 2.56% of trans masculine individuals were HIV positive, highlighting the need for targeted prevention efforts. The researchers called for increased focus on this population's unique needs.
Scientists have identified transcription factor RORC2 as a key player in HIV infection, allowing the virus to persist in immune cells. Inhibiting RORC2 using small molecules can limit viral expansion and prevent replication in healthy individuals and those with HIV.
The US HIV treatment population is projected to increase by 36% by 2030, with older adults making up nearly a quarter of users. The population is expected to shift towards more older age groups, with nearly one in four people with HIV aged 65 or older by 2030.
A large observational cohort study of 134,672 people with HIV found significant disparities in the uptake of dolutegravir, a preferred HIV medication, among women of reproductive age. Only 29% of female patients aged 16-49 years had initiated dolutegravir, compared to 58% of male patients.
According to a new study funded by NIH, adults with HIV are making progress toward the global target of 95% viral suppression, but children and adolescents are not. The researchers estimated that among adults, 79% were virally suppressed after one year of treatment, while among children and adolescents, only 64% reached this milestone.
A new study published in PLOS Global Public Health has mapped the distance to HIV care services in sub-Saharan Africa, highlighting that 7 million people live more than 10 minutes away and 3 million people live more than 30 minutes away. The research aims to develop cost-effective policies for HIV interventions in underserved areas.
A University of California, Riverside-led study found that deafness is a significant barrier to accessing health care and resources for deaf individuals living with HIV. The research highlights the need for improved communication, cultural competency, and accessibility in healthcare services to support aging deaf people with HIV.
Researchers found that activated neutrophils release proteins like galectin-9, triggering chronic inflammation and oxidative stress. Early screening for HIV is crucial, and finding ways to reduce negative effects of the infection could be key to improving outcomes.
A new study found that healthcare providers hold less favorable judgments about patients who inject drugs, leading to potential lack of access to preventive HIV medication. The study highlights the importance of raising awareness and standardizing access to PrEP for all people, regardless of their risk factors.
Researchers at University of California San Diego School of Medicine identified the anterior insula's role in predicting and emotionally processing pain in HIV-DSP patients. The study suggests that reduced anterior insula activity or increased cingulate activity may improve pain outcomes for these patients.
Researchers identified three new human genes influencing HIV acquisition and progression in sub-Saharan Africa. The study provides valuable insights into genetic variants associated with HIV-1C infection and AIDS progression, potentially paving the way for new therapies.
Researchers found that one person relied on high levels of immune cells to control the virus, while another used strong neutralizing antibodies. This study may lead to the development of new treatments to help people with HIV put the virus into remission without taking lifelong medication.
A randomized controlled trial found that adding genotypic resistance testing to routine care didn't improve virologic suppression among HIV patients with first-line antiretroviral therapy failure in public-sector clinics in Uganda and South Africa. The findings highlight the need for effective interventions for persons with virologic f...
Scientists at Einstein College of Medicine have successfully suppressed HIV infections in mice using a novel treatment strategy that boosts the immune system's CD8+ T cells. The therapy, known as synTac, selectively targets HIV-infected T cells, eliminating them from the body and offering a potential path to a functional cure for HIV.
A cross-sectional study found that recent commencement of ART, late HIV stage, and alcohol use are associated with high-risk sexual behavior among HIV patients. The study suggests prioritizing intervention strategies for these individuals to mitigate risky behaviors in HIV-endemic environments.
A team of scientists from the University of Pittsburgh and National Cancer Institute discovered why HIV is rarely the direct cause of cancer. The research found that it requires a specific series of events involving changes in HIV and additional mutations in human genes, resulting in T cell lymphomas. However, the occurrence is rare, a...
A study found that awareness and knowledge of PrEP differ by setting, with lower knowledge in rural Illinois compared to New York City. Despite this, willingness and uptake of PrEP were similar in both urban and rural settings.
Researchers have discovered toxic DNA buildup in the eyes of patients with geographic atrophy, a devastating form of age-related macular degeneration. Common HIV drugs or safer alternatives, such as Kamuvudines, may block inflammation and protect against retinal cell death, offering new hope for treatment.
Researchers at Bielefeld University argue that stigmatization prevented lessons from the HIV pandemic from being adopted by broader parts of society. This has consequences for dealing with the Covid-19 pandemic. The study highlights the importance of including marginalized groups' perspectives in research to learn from their experiences.
Researchers estimate that by 2025, fewer than one in 20 people living with HIV in England will be unaware of their status. The study suggests that combination prevention strategies, including HIV testing and early treatment, are working effectively in reducing undiagnosed HIV cases. However, gaps persist, particularly among heterosexua...
Researchers used exosomes to deliver a novel anti-HIV protein into infected mouse cells, silencing HIV replication and reducing its presence in the bone marrow, spleen, and brain. The treatment shows promise for future delivery methods for HIV and other brain diseases.
Scientists at City of Hope and Griffith University developed a novel anti-HIV protein called ZPAMt that can suppress HIV levels in the bone marrow, spleen, and brain of mice. The protein is delivered using exosomes, nanosized parts of cells that can reach difficult-to-access areas of the body.
West Virginia University researcher Judith Feinberg is integrating services for opioid use disorder, the hepatitis C virus and HIV in 20 primary care clinics across the state. The project aims to address the intertwined opioid and HIV epidemics through efficient and comprehensive care.
A recent study published in the Journal of the American Heart Association found that people living with HIV are at a higher risk of sudden cardiac death compared to those without the virus. The study analyzed data from over 144,000 veterans and found that 26% of those who died from sudden cardiac death had HIV.
A UNSW psychology researcher recommends a set of neurocognitive and mental health questionnaires to harmonize the assessment of long COVID patients. These tests can be used internationally and in various cultural settings to address key questions about the problem, including brain fog and dementia risks.
A Kaiser Permanente study found strong adherence to HIV-prevention drug therapy soon after prescription, but inconsistent use among vulnerable groups. The study suggests that targeted strategies are needed to support the effective use of PrEP in high-risk populations.
Researchers at Albert Einstein College of Medicine and City University of New York Graduate School of Public Health and Health Policy have been awarded a five-year, $14.5 million grant from the National Institutes of Health to continue leading and expand their research on HIV treatment and care in five Central African nations. The effo...
The APPLI study aims to assess the perceptions and preferences of people living with HIV on long-acting injectable antiretroviral therapies. The study will explore how to support adherence and integrate these therapies into Ryan White HIV care settings, potentially improving health outcomes for those struggling with daily oral medicati...
A randomized trial found that a shorter course of rifapentine-isoniazid therapy resulted in significantly higher treatment completion rates compared to a longer daily course. The findings suggest that this regimens can be more effective for preventing tuberculosis disease in individuals with HIV, particularly in high-transmission areas.
A new strategy to improve viral suppression among people living with HIV in NYC has been awarded a 5-year, $3.3 million grant. The D2S intervention aims to bolster medication adherence by delivering client-level viral suppression status reports and targeted capacity-building.
A new epidemiology study reveals crucial trends in HIV/AIDS progression in China from 1990 to 2017. The study highlights the need for effective strategies to reduce mortality rates, especially among men, by intensifying targeted efforts including early identification and diagnosis, high-quality treatment services, and patient retention.
A new strategy for curing HIV targets latent viruses by blocking and excising the virus, offering hope for patients to be taken off daily treatments. The HOPE Collaboratory's approach uses genome editing technology to destroy latent HIV.
The National Institutes of Health has awarded $53 million in annual funding to 10 research organizations to accelerate HIV cure research. A new grant focuses on HIV cure research in infants and children, while expanding international collaborations and exploring innovative approaches such as CRISPR gene-editing technology.
Researchers have developed a simple assessment tool to evaluate patients' risk of cognitive dysfunction in drug treatment programs. The tool combines cognitive measures with patient demographics and health history to produce an overall risk score, helping staff identify accommodations needed for effective treatment.
A new study found that states with low initial use of HIV-prevention drugs continue to fall behind in usage among people at risk for the disease. Researchers urge federal and state governments to close gaps by implementing successful policies from early-adopting states, such as telehealth programs and expanding Medicaid.
A new study found that only 7% of patients who switched from Truvada to Descovy had a documented clinical reason for doing so, highlighting the need for cost-effective PrEP options. The significant price difference between the two medications may be a major barrier to broad and equitable PrEP use in the US.
The Do IT Study assesses switching from INSTIs and TAF-containing regimens to doravirine-based treatments for weight gain reduction. The study aims to inform better strategies for managing ARV side effects in people living with HIV.
A recent study from Scripps Research found that proof-of-concept HIV vaccines generate off-target antibodies that degrade the vaccine's payload, hindering protection. The research provides critical insights for improving HIV subunit trimer vaccines and offers a promising avenue for design improvements.
The NIH has renewed grants for seven regional IeDEA centers, awarding $20.8 million in funding to analyze health data from over 2 million people with HIV. The program aims to accelerate progress toward ending the pandemic by addressing local, national, and global questions about illness and death in people with HIV.